ArticleCureus2026
Maternal Serum and Placental Tissue Expression of PLGF and sFlt-1 in Placenta Accreta Spectrum: Correlation With International Federation of Gynecology and Obstetrics (FIGO) Grading of Disease Severity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAngiogenesis is a central process in the development of the placenta. This balance between pro-angiogenic and anti-angiogenic factors in the decidua can impact the depth of invasion of the placental villi. This study aimed to understand the relationship between serum PLGF (placental growth factor) and sFlt-1 (soluble fms-like tyrosine kinase-1) levels and placental tissue expression of PLGF and sFlt-1 in placenta previa and placenta accreta spectrum (PAS) and to better understand the local and/or systemic role of PLGF and sFlt-1 in the different FIGO PAS grades. METHODOLOGY: A case-control study was conducted in the Department of Obstetrics and Gynecology, Institute of Medical Sciences, Banaras Hindu University, a tertiary care hospital in Northern India, between September 2024 and February 2026. Women with normal placental implantation diagnosed on third trimester ultrasound (USG) were controls, and women with USG showing evidence of placenta previa or PAS were cases. The serum levels of sFlt-1 and PLGF and placenta bed immunohistochemical (IHC) of sFlt-1 and PLGF were analysed between the two groups and between different FIGO grades of PAS. Analysis was done with IBM SPSS Statistics.
resultsFifty women with normal placental implantation (control) and 50 women with placenta previa without invasion or PAS (cases) (placenta previa without invasion -17, FIGO grade 1 PAS-5, grade 2 PAS-12, grade 3 PAS-16) were included in the study. The median age (cases median age = 30, controls = 24, p < 0.001), history of prior caesarean delivery (42 (84%) vs. 6 (12%); p < 0.001) and history of placenta previa in prior pregnancies (21 (42%) vs. 0; p < 0.001) of the cases was significantly higher among the cases as compared to the controls. Serum sFlt-1 (median 5,350 vs. 7,550; p < 0.001) and serum PLGF values (2,550 vs. 5,150, p < 0.001) were lower among cases as compared to controls; there was no difference in the placenta IHC score for sFlt-1 (5 vs. 5; p = 0.770) and PLGF (2 vs. 2; p = 0.106) between groups. In the subgroup analysis of the cases, there was no significant difference between placenta previa without invasion and various grades of PAS with regard to sflt-1, PLGF, sFlt-/PLGF ratio, and placental IHC score for sFlt-1 and PLGF.
conclusionAngiogenic markers, such as PLGF and sFlt-1, are useful adjunctive biomarkers for identifying abnormal placentation. However, their role is limited to detection rather than grading of PAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.